(Q37667754)

21 August 2017

1 reference

title

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

S Gnanakaran

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

publication date

1 September 2009

1 reference

Current Opinion in HIV and AIDS

21 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

page(s)

408-417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120

13 May 2020

cites work

1 reference

12 December 2020

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

1 reference

12 December 2020

Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes

1 reference

12 December 2020

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

1 reference

12 December 2020

Mechanisms of viral membrane fusion and its inhibition

1 reference

12 December 2020

Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop

1 reference

12 December 2020

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

1 reference

12 December 2020

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

1 reference

12 December 2020

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

12 December 2020

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

12 December 2020

Diversity considerations in HIV-1 vaccine selection

1 reference

12 December 2020

Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding

1 reference

12 December 2020

Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

1 reference

12 December 2020

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

1 reference

12 December 2020

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

12 December 2020

Antibody neutralization and escape by HIV-1

1 reference

12 December 2020

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

12 December 2020

Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41.

1 reference

12 December 2020

Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras

1 reference

12 December 2020

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity

1 reference

12 December 2020

Urgently needed: a filter for the HIV-1 vaccine pipeline

1 reference

12 December 2020

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody

1 reference

12 December 2020

Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1

1 reference

12 December 2020

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

12 December 2020

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

1 reference

12 December 2020

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

1 reference

12 December 2020

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

12 December 2020

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

12 December 2020

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

1 reference

12 December 2020

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

12 December 2020

Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding

1 reference

12 December 2020

Alanine scanning mutants of the HIV gp41 loop

1 reference

12 December 2020

PHYML Online--a web server for fast maximum likelihood-based phylogenetic inference

1 reference

12 December 2020

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

1 reference

12 December 2020

Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations

1 reference

12 December 2020

Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques

1 reference

12 December 2020

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody

1 reference

12 December 2020

Quantifying influenza vaccine efficacy and antigenic distance.

1 reference

12 December 2020

Functional impact of HIV coreceptor-binding site mutations

1 reference

12 December 2020

Antibody polyspecificity and neutralization of HIV-1: a hypothesis

1 reference

12 December 2020

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

1 reference

12 December 2020

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

1 reference

12 December 2020

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

1 reference

12 December 2020

Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120.

1 reference

12 December 2020

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

1 reference

12 December 2020

Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations

1 reference

12 December 2020

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

1 reference

12 December 2020

Structural definition of a conserved neutralization epitope on HIV-1 gp120

1 reference

12 December 2020

Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity

1 reference

12 December 2020

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

1 reference

12 December 2020

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

1 reference

12 December 2020

Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.

1 reference

12 December 2020

N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization

1 reference

12 December 2020

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

1 reference

12 December 2020

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection

1 reference

12 December 2020

Antibody-based HIV-1 vaccines: recent developments and future directions

1 reference

12 December 2020

4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response

1 reference

12 December 2020

Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.

1 reference

12 December 2020

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

1 reference

12 December 2020

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

1 reference

12 December 2020

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

1 reference

12 December 2020

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

1 reference

12 December 2020

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

1 reference

12 December 2020

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens

1 reference

12 December 2020

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

1 reference

12 December 2020

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

1 reference

12 December 2020

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

1 reference

12 December 2020

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

1 reference

12 December 2020

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

1 reference

12 December 2020

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination

1 reference

12 December 2020

Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India

1 reference

12 December 2020

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

1 reference

12 December 2020

Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants

1 reference

12 December 2020

Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡

1 reference

12 December 2020

International network for comparison of HIV neutralization assays: the NeutNet report

1 reference

12 December 2020

Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.

1 reference

12 December 2020

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain

1 reference

12 December 2020

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope

1 reference

12 December 2020

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

1 reference

12 December 2020

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

1 reference

12 December 2020

Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein

1 reference

12 December 2020

Structural and functional approaches to the study of protein antigenicity

1 reference

12 December 2020

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

12 December 2020

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

12 December 2020

Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120

1 reference

12 December 2020

Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein

1 reference

12 December 2020

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

12 December 2020

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

12 December 2020

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

12 December 2020

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

12 December 2020

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

12 December 2020

10.1097/COH.0B013E32832F129E

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6426297&resulttype=core&format=json

13 May 2020

1 reference